Roche Holding has announced that its cancer drug, Alecensa, has been granted marketing authorization in China — a beneficiary of China’s recent efforts to speed up approvals.
China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat an aggressive kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals. The approval comes after authorizations in over 57 countries as a first-line treatment.
China has only recently opted to accept overseas trial data to accelerate approvals after high costs and a lack of access to new treatments have forced patients to turn to a growing counterfeit drug market.
Read the press release